NCT01892527View on ClinicalTrials.gov

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

March 31, 2017

Conditions
Colorectal Cancer MetastaticC-met Overexpression
Interventions
DRUG

Tivantinib (ARQ197)

Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks.

Trial Locations (1)

20089

Istituto Clinico Humanitas, Rozzano

All Listed Sponsors
lead

Armando Santoro, MD

OTHER

NCT01892527 - Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects | Biotech Hunter | Biotech Hunter